Dual-purpose package allows submission in both paper and electronic formats
Dual-purpose package allows submission in both paper and electronic formats
Thomson Scientific (Philadelphia, PA, and London, UK) recently released the latest version of its regulatory compliance tool, InSight Publisher version 3.5. The latest iteration enables pharmaceutical companies to create, manage, and publish regulatory submissions in both paper and electronic form using a single software application, potentially saving critical time in the drug development process.
Around the world, regulatory authorities increasingly prefer the electronic format, yet they still require a paper version. With Liquent InSight version 3.5, life science professionals can produce both from a single assembly, using the same thin-client application integrated with the rest of the InSight software suite. Since it is built on the same platform as InSight Manager, which offers registration management and submission tracking capabilities, the entire platform is highly adaptable to different organizational processes and designs.
Thomson Scientific, (215) 386-0100, www.liquent.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.